---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060943"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:37:54.140694+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Onconova Q1 net loss $5.8M; rigosertib achieves complete responses in RDEB-SCC

## Summary
- Cash $34.2M as of March 31, 2023; expects runway into Q1 2024.
- Net loss $5.8M ($0.28/sh) vs $4.1M ($0.20/sh) in Q1 2022; R&D expenses doubled to $4.1M.
- First patient dosed in Phase 1/2a trial of narazaciclib plus letrozole in LGEEC; preliminary data expected Q4 2023.
- Both evaluable patients in rigosertib RDEB-SCC trial achieved complete cutaneous remissions; FDA Type B meeting requested.
- Entered collaboration with Pangea Biomed to identify biomarkers for rigosertib response.

## SEC filing metadata
- accession: 0001104659-23-060943
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/0001104659-23-060943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/tm2315886d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060943
- JSON: https://secwatch.observer/filing/0001104659-23-060943.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060943.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported the three months ended March 31, 2023 results: net income $5.8 million, EPS $0.28 per share.
  - Period: the three months ended March 31, 2023
  - Net income: $5.8 million
  - EPS: $0.28 per share
  - Result: reported results
  source text: Net loss for the first quarter of 2023 was $5.8 million, or $0.28 per share on 20.9 million weighted shares outstanding, compared with a net loss of $4.1 million, or $0.20 per share for the first quarter of 2022 on 20.9 million weighted shares outstanding.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/0001104659-23-060943-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.